Abstract
Despite decades of research, both primary and metastatic brain tumors remain intractable clinical problems. While the kynurenine (KYN) pathway of tryptophan metabolism has been well explored in other cancer types, there are few studies of human brain tumors. The rate-limiting enzymes of the conversion of tryptophan to kynurenine (both forms of indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO2)) have been studied predominantly in gliomas with in vitro methods, in vivo animal studies, and ex vivo tissue studies of surgically resected specimens. In these studies, IDO1 has been shown regulated by interferon-γ (as in other cancer types) and TDO2 by the glucocorticoid receptor. IDO and TDO2 have also been positively correlated with tumor grade and negatively correlated with patient survival in glioma. One seminal study also identified KYN as an activator of the aryl hydrocarbon receptor (not previously shown in any other cancer types). Therefore, the KYN pathway may represent new opportunities for treatment strategies for brain tumors.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- 3-HK:
-
3-Hydroxykynurenine
- AMT:
-
α-[11C]-methyl-L-tryptophan
- TCDD:
-
2,3,7,8-Tetrachlorodibenzo-p-dioxin
- AhR:
-
Aryl hydrocarbon receptor
- CNS:
-
Central nervous system
- FKBP52:
-
FK506-binding protein 52kDa
- GBM:
-
Glioblastoma
- GR:
-
Glucocorticoid receptor
- IDO:
-
Indoleamine 2,3-dioxygenase
- IFN-γ:
-
Interferon-γ
- KYNA:
-
Kynurenic acid
- KYN:
-
Kynurenine
- KMO:
-
Kynurenine 3-monooxygenase
- MRI:
-
Magnetic resonance imaging
- MEN:
-
Meningioma
- MBT:
-
Metastatic brain tumor
- PET:
-
Positron emission tomography
- QUIN:
-
Quinolinic acid
- Tregs:
-
Regulatory T cells
- TRP:
-
Tryptophan
- TDO2:
-
Tryptophan 2,3-dioxygenase
References
Bollig-Fischer A, Michelhaugh SK, Ali-Fehmi R, Mittal S. The molecular genomics of metastatic brain tumors. OA Mol Oncol. 2013;1(1):6.
Zitron IM, Kamson DO, Kiousis S, Juhasz C, Mittal S. In vivo metabolism of tryptophan in meningiomas is mediated by indoleamine 2,3-dioxygenase 1. Cancer Biol Ther. 2013;14(4):333–9. doi:10.4161/cbt.23624.
Xie Q, Mittal S, Berens ME. Targeting adaptive glioblastoma: an overview of proliferation and invasion. Neuro Oncol. 2014;16(12):1575–84. doi:10.1093/neuonc/nou147.
Bollig-Fischer A, Michelhaugh SK, Wijesinghe P, Dyson G, Kruger A, Palanisamy N et al. Cytogenomic profiling of breast cancer brain metastases reveals potential for repurposing targeted therapeutics. Oncotarget. 2015;6(16):14614–14624.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109. doi:10.1007/s00401-007-0243-4.
Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492–507. doi:10.1056/NEJMra0708126.
Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012;13(7):465–77. doi:10.1038/nrn3257.
Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011;478(7368):197–203. doi:10.1038/nature10491.
Eastman CL, Guilarte TR. Cytotoxicity of 3-hydroxykynurenine in a neuronal hybrid cell line. Brain Res. 1989;495(2):225–31.
Di Serio C, Cozzi A, Angeli I, Doria L, Micucci I, Pellerito S, et al. Kynurenic acid inhibits the release of the neurotrophic fibroblast growth factor (FGF)-1 and enhances proliferation of glia cells, in vitro. Cell Mol Neurobiol. 2005;25(6):981–93. doi:10.1007/s10571-005-8469-y.
Walczak K, Deneka-Hannemann S, Jarosz B, Zgrajka W, Stoma F, Trojanowski T, et al. Kynurenic acid inhibits proliferation and migration of human glioblastoma T98G cells. Pharmacol Rep. 2014;66(1):130–6. doi:10.1016/j.pharep.2013.06.007.
Cano OD, Neurauter G, Fuchs D, Shearer GM, Boasso A. Differential effect of type I and type II interferons on neopterin production and amino acid metabolism in human astrocyte-derived cells. Neurosci Lett. 2008;438(1):22–5. doi:10.1016/j.neulet.2008.04.046. Epub Apr 18.
Colborn T, vom Saal FS, Soto AM. Developmental effects of endocrine-disrupting chemicals in wildlife and humans. Environ Health Perspect. 1993;101(5):378–84.
Ott M, Litzenburger UM, Rauschenbach KJ, Bunse L, Ochs K, Sahm F, et al. Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway. Glia. 2014;5(10):22734.
Soichot M, Vaast A, Vignau J, Guillemin GJ, Lhermitte M, Broly F, et al. Characterization of functional polymorphisms and glucocorticoid-responsive elements in the promoter of TDO2, a candidate gene for ethanol-induced behavioural disorders. Alcohol Alcohol. 2013;48(4):415–25. doi:10.1093/alcalc/agt028.
Posadas Salas MA, Srinivas TR. Update on the clinical utility of once-daily tacrolimus in the management of transplantation. Drug Des Devel Ther. 2014;8:1183–94. doi:10.2147/DDDT.S55458.
Wainwright DA, Balyasnikova IV, Chang AL, Ahmed AU, Moon KS, Auffinger B, et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res. 2012;18(22):6110–21. doi:10.1158/078-0432.CCR-12-2130. Epub 012 Aug 29.
Seligman AM, Shear MJ, Alexander L. Studies in carcinogenesis: VIII. Experimental production of brain tumors in mice with methylcholanthrene. Am J Cancer. 1939;37(3):364–95. doi:10.1158/ajc.1939.364.
Jacobs VL, Valdes PA, Hickey WF, De Leo JA. Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model. ASN Neuro. 2011;3(3). doi:10.1042/an20110014.
Denison MS, Nagy SR. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol. 2003;43:309–34. doi:10.1146/annurev.pharmtox.43.100901.135828.
Vogel CF, Goth SR, Dong B, Pessah IN, Matsumura F. Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase. Biochem Biophys Res Commun. 2008;375(3):331–5. doi:10.1016/j.bbrc.2008.07.156.
Snodgrass SR, Iversen LL. Amino acid uptake into human brain tumors. Brain Res. 1974;76(1):95–107.
Hubner KF, Purvis JT, Mahaley Jr SM, Robertson JT, Rogers S, Gibbs WD, et al. Brain tumor imaging by positron emission computed tomography using 11C-labeled amino acids. J Comput Assist Tomogr. 1982;6(3):544–50.
Vezzani A, Gramsbergen JB, Versari P, Stasi MA, Procaccio F, Schwarcz R. Kynurenic acid synthesis by human glioma. J Neurol Sci. 1990;99(1):51–7.
Vezzani A, Gramsbergen JB, Speciale C, Schwarcz R. Production of quinolinic acid and kynurenic acid by human glioma. Adv Exp Med Biol. 1991;294:691–5.
Heyes MP, Saito K, Milstien S, Schiff SJ. Quinolinic acid in tumors, hemorrhage and bacterial infections of the central nervous system in children. J Neurol Sci. 1995;133(1–2):112–8.
Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9(10):1269–74. doi:10.1038/nm934.
Mitsuka K, Kawataki T, Satoh E, Asahara T, Horikoshi T, Kinouchi H. Expression of indoleamine 2,3-dioxygenase and correlation with pathological malignancy in gliomas. Neurosurgery. 2013;72(6):1031–8; discussion 8–9. doi: 10.1227/NEU.0b013e31828cf945.
Adams S, Teo C, McDonald KL, Zinger A, Bustamante S, Lim CK, et al. Involvement of the kynurenine pathway in human glioma pathophysiology. PLoS One. 2014;9(11), e112945. doi:10.1371/journal.pone.0112945.
Juhasz C, Dwivedi S, Kamson DO, Michelhaugh SK, Mittal S. Comparison of amino acid positron emission tomographic radiotracers for molecular imaging of primary and metastatic brain tumors. Mol Imaging. 2014;13. doi:10.2310/7290.2014.00015.
Alkonyi B, Barger GR, Mittal S, Muzik O, Chugani DC, Bahl G, et al. Accurate differentiation of recurrent gliomas from radiation injury by kinetic analysis of alpha-11C-methyl-L-tryptophan PET. J Nucl Med. 2012;53(7):1058–64. doi:10.2967/jnumed.111.097881. Epub 2012 May 31.
Kamson DO, Mittal S, Buth A, Muzik O, Kupsky WJ, Robinette NL, et al. Differentiation of glioblastomas from metastatic brain tumors by tryptophan uptake and kinetic analysis: a positron emission tomographic study with magnetic resonance imaging comparison. Mol Imaging. 2013;12(5):327–37.
Kamson DO, Mittal S, Robinette NL, Muzik O, Kupsky WJ, Barger GR, et al. Increased tryptophan uptake on PET has strong independent prognostic value in patients with a previously treated high-grade glioma. Neuro Oncol. 2014;1:1.
Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 2007;67(15):7082–7. doi:10.1158/0008-5472.CAN-07-1872.
Acknowledgments
This work is supported by NIH/NCI R01 grant CA123451 (SM) and Strategic Research Support from the Karmanos Cancer Institute (SM).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Michelhaugh, S.K., Varadarajan, K., Guastella, A.R., Mittal, S. (2015). Role of Kynurenine Pathway in Neuro-oncology. In: Mittal, S. (eds) Targeting the Broadly Pathogenic Kynurenine Pathway. Springer, Cham. https://doi.org/10.1007/978-3-319-11870-3_22
Download citation
DOI: https://doi.org/10.1007/978-3-319-11870-3_22
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-11869-7
Online ISBN: 978-3-319-11870-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)